AKBM — Aker Biomarine ASA Share Price
0.000.00%
Last trade - 00:00- NOK4.34bn
- NOK6.11bn
- $335.30m
- 46
- 45
- 29
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.02 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 1.88 | ||
| Price to Free Cashflow | 15.51 | ||
| Price to Sales | 1.33 | ||
| EV to EBITDA | 9.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.43% | ||
| Return on Equity | -1.07% | ||
| Operating Margin | 1.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 246.17 | 288.59 | 262.06 | 277.2 | 335.3 | 271.06 | 248.07 | 16.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aker Biomarine ASA is a Norway-based biotech innovator and Antarctic krill-harvesting company. It consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine’s focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.
Directors
- Ola Snove CHM (44)
- Matts Johansen CEO (45)
- Katrine Klaveness CFO
- Hege Spaun CHO
- Webjorn Barstad EVP (56)
- Tim De Hass EVP
- Tone Lorentzen EVP
- Shauna McNeill EVP
- Sigve Nordrum EVP
- Todd Norton EVP
- Trond Smedsrud EVP
- Oyvind Eriksen DRC (57)
- Line Johnsen DRC
- Frank Reite DRC (51)
- Kjell Rokke DRC (63)
- Sindre Skjong DRC (45)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- July 21st, 2014
- Public Since
- July 6th, 2020
- No. of Employees
- 373
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 87,685,014
- Address
- Oksenoyveien 10,, LYSAKER, 1327
- Web
- https://www.akerbiomarine.com/
- Phone
- +47 24130000
- Contact
- Christopher Vinter
- Auditors
- PricewaterhouseCoopers AS
Upcoming Events for AKBM
Q4 2024 Aker Biomarine ASA Earnings Release
Similar to AKBM
Akva ASA
Oslo Stock Exchange
Andfjord Salmon AS
Oslo Stock Exchange
Arctic Fish Holding AS
Oslo Stock Exchange
Atlantic Sapphire ASA
Oslo Stock Exchange
Austevoll Seafood ASA
Oslo Stock Exchange
FAQ
What is the Aker Biomarine ASA share price?
As of Today at 19:09 UTC, shares in Aker Biomarine ASA are trading at NOK49.50. This share price information is delayed by 15 minutes.
How has the Aker Biomarine ASA share price performed this year?
Shares in Aker Biomarine ASA last closed at NOK49.50 and the price had moved by +24.3% over the past 365 days. In terms of relative price strength the Aker Biomarine ASA share price has outperformed the FTSE Global All Cap Index by +7.29% over the past year.
What are the analyst and broker recommendations for Aker Biomarine ASA?
The overall consensus recommendation for Aker Biomarine ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aker Biomarine ASA dividend yield?
Aker Biomarine ASA does not currently pay a dividend.
Does Aker Biomarine ASA pay a dividend?
Aker Biomarine ASA does not currently pay a dividend.
When does Aker Biomarine ASA next pay dividends?
Aker Biomarine ASA does not currently pay a dividend.
How do I buy Aker Biomarine ASA shares?
To buy shares in Aker Biomarine ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aker Biomarine ASA?
As of the previous close price of NOK49.50, shares in Aker Biomarine ASA had a market capitalisation of NOK4.34bn.
Where are Aker Biomarine ASA shares listed?
Here are the trading details for Aker Biomarine ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: AKBM
What kind of share is Aker Biomarine ASA?
Based on an overall assessment of its quality, value and momentum Aker Biomarine ASA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aker Biomarine ASA share price forecast for 2024?
The analyst consensus target price for shares in Aker Biomarine ASA is NOK75.92. That is 53.36% above the last closing price of NOK49.50.
Analysts covering Aker Biomarine ASA currently have a consensus Earnings Per Share (EPS) forecast of -$0.01 for the next financial year.
Find out moreWhat is the trend in the Aker Biomarine ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aker Biomarine ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -31.23%.
As of the last closing price of NOK49.50, shares in Aker Biomarine ASA were trading -28.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aker Biomarine ASA PE Ratio?
The Aker Biomarine ASA PE ratio based on its reported earnings over the past 12 months is 35.02. The shares last closed at NOK49.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aker Biomarine ASA?
Aker Biomarine ASA's management team is headed by:
- Ola Snove - CHM
- Matts Johansen - CEO
- Katrine Klaveness - CFO
- Hege Spaun - CHO
- Webjorn Barstad - EVP
- Tim De Hass - EVP
- Tone Lorentzen - EVP
- Shauna McNeill - EVP
- Sigve Nordrum - EVP
- Todd Norton - EVP
- Trond Smedsrud - EVP
- Oyvind Eriksen - DRC
- Line Johnsen - DRC
- Frank Reite - DRC
- Kjell Rokke - DRC
- Sindre Skjong - DRC